Abstract
Vasoactive intestinal peptide (VIP) is a neuropeptide with a broad distribution in the body that exerts very important pleiotropic functions in several systems. The present work reviews the immunology of VIP. Being daring, this neuropeptide could be included in the group of cytokines since it is produced and secreted by different immunocompetent cells in response to various immune signals, plays a broad spectrum of immunological functions, and exerts them, in a paracrine and/orautocrine way, through three different specific receptors. Although VIP has been classically considered as an immunodepressant agent, and its main described role has been as an anti-inflammatory factor, several evidences suggest that a better way to see this peptide is as a modulator of the homeostasis of the immune system. In the last decade, the pharmacology of VIP has spectacularly grown, and VIP itself, as well as more stable VIP-derived agents, have been used or proposed as efficient therapeutical treatments of several disorders, specially inflammatory and autoimmune diseases, such as septic shock, rheumatoid arthritis, multiple sclerosis, Crohns disease and autoimmune diabetes. A broad field of perspectives is actually open, and further investigations will help us to definitively understand the immunology of this “very important peptide”
Current Pharmaceutical Design
Title: Immunology of VIP: A Review and Therapeutical Perspectives
Volume: 7 Issue: 2
Author(s): R.P. Gomariz, C. Martinez, C. Abad, J. Leceta and M. Delgado
Affiliation:
Abstract: Vasoactive intestinal peptide (VIP) is a neuropeptide with a broad distribution in the body that exerts very important pleiotropic functions in several systems. The present work reviews the immunology of VIP. Being daring, this neuropeptide could be included in the group of cytokines since it is produced and secreted by different immunocompetent cells in response to various immune signals, plays a broad spectrum of immunological functions, and exerts them, in a paracrine and/orautocrine way, through three different specific receptors. Although VIP has been classically considered as an immunodepressant agent, and its main described role has been as an anti-inflammatory factor, several evidences suggest that a better way to see this peptide is as a modulator of the homeostasis of the immune system. In the last decade, the pharmacology of VIP has spectacularly grown, and VIP itself, as well as more stable VIP-derived agents, have been used or proposed as efficient therapeutical treatments of several disorders, specially inflammatory and autoimmune diseases, such as septic shock, rheumatoid arthritis, multiple sclerosis, Crohns disease and autoimmune diabetes. A broad field of perspectives is actually open, and further investigations will help us to definitively understand the immunology of this “very important peptide”
Export Options
About this article
Cite this article as:
R.P. Gomariz , C. Martinez , C. Abad , J. Leceta and M. Delgado , Immunology of VIP: A Review and Therapeutical Perspectives, Current Pharmaceutical Design 2001; 7 (2) . https://dx.doi.org/10.2174/1381612013398374
DOI https://dx.doi.org/10.2174/1381612013398374 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Venom Peptide Modulators of the Immune System
Inflammation & Allergy - Drug Targets (Discontinued) Association of EGF rs4444903 and XPD rs13181 Polymorphisms with Cutaneous Melanoma in Caucasians
Medicinal Chemistry Herbal Nano Formulations: Patent and Regulatory Overview
Applied Clinical Research, Clinical Trials and Regulatory Affairs Insulin-Sensiting Effects of Tumor Necrosis Factor Alpha Inhibitors in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Reviews on Recent Clinical Trials Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design Gene Therapy for Arthritis
Current Drug Targets Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Current Pharmaceutical Design Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Current Neuropharmacology Editorial (Thematic Issue: Therapeutic Applications of Advanced Drug Delivery Systems)
Current Pharmaceutical Design Update on the Management of Spondyloarthritis in Asian Countries
Current Rheumatology Reviews Clinical Applicability of Sequence Variations in Genes Related to Drug Metabolism
Current Drug Metabolism Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets Autoinflammation and Immunomodulation in Inflammatory Fibromyalgia Syndrome- A Review
Current Rheumatology Reviews Cyclooxygenase Inhibitory Natural Products: Current Status
Current Medicinal Chemistry A Review on Expedient Assets of Polymers Employed in Novel Topical Formulation for Successful Treatment of Arthritis
Current Applied Polymer Science The Use of the Zebrafish Model to Aid in Drug Discovery and Target Validation
Current Topics in Medicinal Chemistry Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews Emerging Anti-inflammatory Therapies for Atherosclerosis
Current Pharmaceutical Design Hemolysis and Rhabdomyolysis after Marathon and Long Distance Running
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)